Home » Stocks » Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. (EGRX)

Stock Price: $47.72 USD 1.33 (2.87%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $47.19 -0.53 (-1.10%) Aug 3, 4:13 PM

Stock Price Chart

Key Info

Market Cap 709.21M
Revenue (ttm) 192.13M
Net Income (ttm) 2.47M
Shares Out 13.69M
EPS (ttm) 0.18
PE Ratio 265.11
Forward PE 16.21
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $47.72
Previous Close $46.39
Change ($) 1.33
Change (%) 2.87%
Day's Open 46.63
Day's Range 45.70 - 47.95
Day's Volume 141,225
52-Week Range 33.80 - 64.94

More Stats

Market Cap 709.21M
Enterprise Value 653.98M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 13.69M
Float 10.98M
EPS (basic) 0.19
EPS (diluted) 0.18
FCF / Share 2.33
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.38%
FCF Yield 4.50%
Payout Ratio n/a
Shares Short 2.00M
Short Ratio 10.55
Short % of Float 23.98%
Beta 1.00
PE Ratio 265.11
Forward PE 16.21
P/FCF Ratio 22.24
PS Ratio 3.69
PB Ratio 3.49
Revenue 192.13M
Operating Income 13.68M
Net Income 2.47M
Free Cash Flow 31.89M
Net Cash 55.24M
Net Cash / Share 3.72
Gross Margin 70.26%
Operating Margin 7.12%
Profit Margin 1.30%
FCF Margin 16.60%
ROA 2.75%
ROE 1.38%
ROIC 10.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(8.28% upside)
Current: $47.72
Target: 51.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-8.17%-9.88%24.92%186.11%246.76%39.62%438.76%-
Gross Profit13515118013450.587.396.30-0.63
Operating Income21.8235.8566.6152.562.56-18.76-8.46-19.83
Net Income14.3131.9051.9481.452.57-17.98-6.05-19.38
Shares Outstanding13.7514.7715.1015.5315.259.963.041.65
Earnings Per Share1.
EPS Growth-51.67%-36.09%-34.07%3000%----
Operating Cash Flow55.9952.3858.9253.21-9.72-13.84-5.88-15.55
Capital Expenditures-0.78-0.13-4.44-1.59-1.88-0.05-0.04-0.03
Free Cash Flow55.2152.2554.4851.62-11.60-13.89-5.92-15.58
Cash & Equivalents11078.7911552.8279.0842.7210.466.57
Total Debt38.5644.4147.78----8.57
Net Cash / Debt71.2234.3966.8852.8279.0842.7210.46-2.00
Book Value17916117915190.3433.10-87.93-93.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Eagle Pharmaceuticals, Inc.
Country United States
Employees 108
CEO Scott L. Tarriff

Stock Information

Ticker Symbol EGRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: EGRX
IPO Date February 12, 2014


Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.